The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: Results from the Cardiovascular Health Study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 7, 1999, Pages 1776-1783

  Tracy, Russell P ^a,g   Arnold, Alice M ^b   Ettinger, Walter ^c   Fried, Linda ^d   Meilahn, Elaine ^e   Savage, Peter ^f  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g UNIVERSITY OF VERMONT   (United States)

Author keywords

Atherosclerosis; Cardiovascular diseases; Fibrinogen; Risk factors; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN;

AGED; AGING; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STROKE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

EID: 0033000422     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.7.1776     Document Type: Article

References (67)

1. Ernst E, Resch K. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-963.
2. Miller G. Hemostasis and cardiovascular risk. Arch Pathol Lab Med. 1992;116:1318-1321.
3. Meade T, Ruddock V, Stirling Y, Chakrabarti R, Miller G. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342: 1076-1079.
4. Meade T, Brozovic M, Chakrabarti R, Haines A, Imeson J, Mellows S, Miller G, North W, Stirling Y, Thompson S. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
5. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
6. Stone M, Thorp J. Plasma fibrinogen - a major coronary risk factor. J R Col Gen Pract. 1985;35:565-569.
7. Kannel W, D'Agostino R, Belanger A. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol. 1992;2:457-466.
8. Yarnell J, Baker I, Sweetnam P, Bainton D, O'Brien J, Whitehead P, Elwood P. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation. 1991;83:836-844.
9. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-59.
10. Folsom A, Wu K, Rosamond W, Sharrett A, Chambless L. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997; 96:1102-1108.
11. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol. 1997;17:1539-1544.
12. Carvalho de Sousa J, Azevedo J, Soria C, Barros F, Ribeiro C, Parreira F, Caen J. Factor VII hyperactivity in acute myocardial thrombosis: a relation to the coagulation activation. Thrombos Res. 1988;51:165-173.
13. Cigolini M, Targher G, Seidell J, Schiavon R, Tonoli M, Muggeo M, De Sandre G. Plasma factor VII and its relation to adipose tissue fatty acids and other atherogenic risk factors in healthy men. Eur J Clin Invest. 1996;26:247-253.
14. Hoffman C, Shah A, Sodums M, Hultin M. Factor VII activity state in coronary artery disease. J Lab Clin Med. 1988;111:475-481.
15. Hoffman C, Miller R, Lawson W, Hultin M. Elevation of factor VII activity and mass in young adults at risk of ischaemic heart disease. J Am Coll Cardiol. 1989;14:941-946.
16. Mann K. Factor VII assays, plasma triglyceride levels and cardiovascular disease risk. Arteriosclerosis. 1989;9:783-784.
17. Miller G, Martin J, Webster J, Wilkes H, Miller N, Wilkinson W, Meade T. Association between dietary fat intake and plasma factor VII coagulant activity: a predictor of cardiovascular mortality. Athersclerosis. 1986;60: 269-277.
18. Moor E, Silviera A, van't Hooft F, Suontaka A, Erikkson P, Blomback M, Hamsten A. Coagulation factor VII mass and activity in men with myocardial infarction at a young age. Arterioscler Thromb Vasc Biol. 1995; 15:655-664.
19. Folsom A, Wu K, Rosamond W, Sharrett A, Chambless L. Hemostatic factors and incidence of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1996;93:622. Abstract.
20. Ridker P, Vaughan D, Stampfer M, Manson J, Hennekens C. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
21. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
22. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
23. Meade T. The epidemiology of haemostatic and other variables in coronary artery disease. In: Verstraete M, Vermylen J, Lijnen H, Arnout J, eds. Thrombosis and Haemostasis 1987. Leuven, Belgium: International Society on Thrombosis and Haemostasis and Leuven University Press; 1987:37-59.
24. Kannel W, Wolf P, Castelli W, D'Agostino R. Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA. 1987;258: 1183-1186.
25. Fried L, Borhani N, Enright P, Furberg C, Gardin J, Kronmal R, Kuller L, Manolio T, Mittelmark M, Newman A, O'Leary D, Psaty B, Rautaharju P, Tracy R, Weiler P, for the CHS Research Group: the Cardiovascular Health Study - design and rationale. Ann Epidemiol. 1991;1:263-276.
26. Tell G, Fried L, Hermanson B, Manolio T, Newman A, Borhani N. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:358-366.
27. Psaty B, Lee M, Savage P, Rutan G, German P, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. J Clin Epidemiol. 1992;45:683-692.
28. Rutan G, Lind B, Bild D, Kittner S, LaBaw F, Tell G. Hypotension in older adults: the Cardiovascular Health Study. Hypertension. 1992;19: 508-519.
29. Psaty B, Furberg C, Kuller L, Borhani N, Rautaharju P, O'Leary D, Bild D, Robbins J, Fried L, Reid C. Isolated systolic hypertension and subclinical cardiovascular disease in the elderly: initial findings from the Cardiovascular Health Study. JAMA, 1992;268:1287-1291.
30. Furberg C, Manolio T, Psaty B, Bild D, Borhani N, Newman A, Tabatznik B, Rautaharju P. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Am J Cardiol. 1992;69:1329-1335.
31. O'Leary D, Polak J, Wolfson S, Bond M, Bommer W, Sheth S, Psaty B, Sharrett A, Manolio T, for CHS Investigators. Use of sonography to evaluate carotid atherosclerosis in the elderly: the Cardiovascular Health Study. Stroke. 1991;22:1155-1163.
32. Gardin J, Wong N, Bommer W, Klopfenstein H, Smith V, Tabatznik B, Siscovick D, Lobodzinski S, Anton-Culver H, Manolio T. Echocardiographic design of a multi-center investigation of free-living elderly subjects: the Cardiovascular Health Study. J Am Soc Echocardiogr. 1992;5: 63-72.
33. Cushman M, Cornell E, Howard P, Bovill E, Tracy R. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41:264-270.
34. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;7: 1183-1197.
35. Rose G, Blackburn H. Cardiovascular Survey Methods. Monogr Ser World Health Organ. 1968;56:1-188.
36. Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O'Leary D, Psaty B, Robbins J. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol. 1994;139:1164-1179.
37. Kuller L, Shemanski L, Psaty B, Borhani N, Gardin J, Haan M, O'Leary D, Savage P, Tell G, Tracy R. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation. 1995;92:720-726.
38. Newman A, Siscovick D, Manolio T, Polak J, Fried L, Borhani N, Wolfson S, for the CHS Investigators. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation. 1993;88: 837-845.
39. O'Leary D, Polak J, Kronmal R, Kittner S, Bond G, Wolfson S, Bommer W, Price T, Gardin J, Savage P, on behalf of the CHS Collaborative Research Group. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke. 1992; 23:1752-1760.
40. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies: a classification system. Circulation. 1960;21:1160-1175.
41. Rautaharju P, Maclnnis P, Warren J. Methodology of ECG interpretation in the Dalhousie Program: NOVACODE ECG classification procedures for clinical trials and population health surveys. Methods Inf Med. 1990; 29:362-374.
42. Gardin J, Siscovick D, Anton-Culver H, Lynch J, Smith V, Klopfenstein S, Bommer W, Fried L, O'Leary D, Manolio T. Sex, age, and disease affect echocardiographic left ventricular mass and systolic function in the free-living elderly. Circulation. 1995;91:1739-1748.
43. Ives D, Fitzpatrick A, Bild D, Psaty B, Kuller L, Crowley P, Cruise R, Theroux S. Surveillance and ascertainment of cardiovascular events. Ann Epidemiol. 1995;5:278-285.
44. Psaty B, Kuller L, Bild D, Burke G, Kittner S, Mittelmark M, Price T, Rautaharju P, Robbins J. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995;5: 270-277.
45. Seligsohn U, Osterud B, Griffin J, Rapaport S. Evidence for the participation of both activated factor XII and activated factor IX in the cold promoted-activation of factor VII. Thromb Res. 1978;13:1049-1056.
46. Clauss A. Gerinnungs-physiologische schnell-methode zur bestimmung des fibrinogens. Acta Haematol. 1957;17:237-246.
47. Tracy R, Bovili E, Fried L, Heiss G, Lee M, Polak J, Psaty B, Savage P. The distribution of coagulation factors VII, VIII and fibrinogen in adults over the age of 65 years: results from the Cardiovascular Health Study. Ann Epidemiol. 1992;2:509-519.
48. Tracy R. Atherosclerosis, thrombosis and inflammation: a question of linkage. Fibrinolysis Proteolysis. 1997;11(suppl 1):137-142.
49. Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both? Circulation. 1998;97:2000-2002. Editorial.
50. Ettinger W, Harris T, Verdery R, Tracy R, Kouba E. Evidence for inflammation as a cause of hypocholesterolemia in older people. J Am Geriatr Soc. 1995;43:264-266.
51. Cushman M, Psaty B, Macy E, Bovill E, Cornell E, Kuller L, Tracy R. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol. 1996;16:1163-1169.
52. Cushman M, Lemaitre R, Kuller L, Psaty B, Macy E, Sharrett A, Tracy R. Fibrinolytic activation markers predict myocardial infarction in the elderly: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:493-498.
53. de Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, Bruschke AV, Kluft C. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen - REGRESS group. Arterioscler Thromb Vasc Biol. 1998;18:265-271.
54. Zito F, Di Castelnuovo A, Amore C, D'Orazio A, Donati MB, Iacoviello L. Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels: a case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol. 1997;17:3489-3494.
55. Carter AM, Mansfield MW, Stickland MH, Grant PJ. Beta-fibrinogen gene-455 G/A polymorphism and fibrinogen levels: risk factors for coronary artery disease in subjects with NIDDM. Diabetes Care. 1996;19:1265-1268.
56. Scarabin P, Bara L, Ricard S, Poirier O, Cambou J, Arveiler D, Luc G, Evans A, Samama M, Cambien F. Genetic variation at the B-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. Arterioscler Thromb. 1993;13:886-891.
57. Miller G, Stirling Y, Esnouf M, Heinrich J, van der Loo J, Kienast J, Wu K, Morrissey J, Meade T, Martin J, Imeson J, Cooper J, Finch A. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost. 1994;71:38-48.
58. Meade T, Chakrabarti R, Haines A, North W, Stirling Y, Thompson S. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980;1:1050-1054.
59. Tuddenham E. Factor VIII. In: High K, Roberts H, eds. Molecular Basis of Thrombosis and Hemostasis. New York. NY: Marcel Dekker, Inc; 1995:167-196.
60. Brandt J. Measurement of factor VIII: a potential risk factor for vascular disease. Arch Pathol Lab Med. 1993;117:48-51.
61. Cushman M, Yanez D, Psaty B, Fried L, Heiss G, Lee M, Polak J, Savage P, Tracy R, for the CHS Investigators. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Am J Epidemiol. 1996;143: 665-676.
62. Mettinger K, Nyman D, Kjellin K, Siden A, Soderstrom C. Factor VIII related antigen, antithrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebrovascular disease. J Neurol Sci. 1979;41:31-38.
63. Downton S, Colten H. Acute phase reactants in inflammation and infection. Semin Hematol. 1988;25:84-94.
64. Kronmal R, Cain K, Ye Z, Omenn G. Total serum cholesterol levels and mortality risk as a function of age. Arch Intern Med. 1993;153: 1065-1073.
65. Steering Committee of the Physician's Health Study Research Group. Final report on the aspirin component of the ongoing Physician's Health Study. N Engl J Med. 1989;821:129-135.
66. Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
67. Ernst E. Lowering the plasma fibrinogen concentration with drugs. Clin Pharm. 1992;11:968-971.